Opinion|Videos|November 12, 2024
Fezolinetant in Focus: Key Findings From the SKYLIGHT Trials
Key Takeaways
- Fezolinetant's approval was based on SKYLIGHT 1, 2, and 4 trials, which were randomized, double-blind, and placebo-controlled.
- The trials focused on women with moderate to severe vasomotor symptoms, evaluating fezolinetant's safety and efficacy.
Panelists discuss the methodologies of the SKYLIGHT 1, SKYLIGHT 2, and SKYLIGHT 4 trials that supported the approval of fezolinetant for moderate to severe vasomotor symptoms (VMS) and examine the key safety and efficacy results derived from these studies.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- (SMITH) The approval of fezolinetant for moderate to severe VMS was based on the
SKYLIGHT 1 ,SKYLIGHT 2 , andSKYLIGHT 4 trials. Briefly describe the methodology of these studies. - (FIFFICK) What were the key safety and efficacy results from the SKYLIGHT studies?
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
NYC Legionnaires Disease Cluster Slows as Cooling Tower Remediation Continues
2
Female Newborns More Likely to Miss Vitamin K Prophylaxis, Hepatitis B Birth Dose
3
New Survey Highlights Quality-of-Life Benefits of Dry Eye Disease Treatment
4
FDA Approved At-Home SC Lecanemab Initiation Dose for Early Alzheimer Disease
5